pDJA1, a cardiac specific gene, corresponding proteins, and uses thereof
View Patent ↗The present invention provides novel nucleic acid and protein sequences for methods and compositions for treating, screening, and diagnosing cardiovascular disease and methods for using these genes and gene products for prevention of cardiac cell death and prevention of cardiac tissue damage resulting from ischemic events in cardiac tissue, as well as other tissue that is subject to damage resulting from an ischemic event. The genes, gene products and agents of the invention are also useful for treating other related clinical or coronary events such as angina, myocardial infarct (MI), and stroke, for monitoring the effectiveness of their treatment, and for drug development. The genes, gene products and agents of the present invention are also provided as pharmaceutical compositions for treatment of cardiovascular disease, ischemic heart disease, myocardial infarct and related conditions. Kits are also provided for the diagnosis, treatment and prognosis of cardiac diseases and related conditions.
1. An isolated polypeptide, comprising an amino acid sequence of a pDJA1 protein having at least 98% sequence identity with SEQ ID NO: 2, wherein said polypeptide protects against an ischemic event.
2. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.
3. A biomarker comprising the amino acid sequence of SEQ ID NO:2, wherein said biomarker is associated with and/or predictive of cardiovascular disease, wherein said cardiovascular disease is selected from the group consisting of coronary artery disease and carotid artery disease and other related conditions related to or resulting from an ischemic event.
4. A composition comprising a therapeutically effective amount of an isolated pDJA1 polypeptide having the amino acid sequence of SEQ ID NO:2 and a pharmaceutically acceptable carrier, wherein said isolated pDJA1 polypeptide protects against an ischemic event.
5. A composition comprising a therapeutically effective amount of an isolated pDJA1 polypeptide having an amino acid sequence at least 98% identical to SEQ ID NO: 2 and a pharmaceutically acceptable carrier, wherein the isolated pDJA1 polypeptide protects against an ischemic event.